Durable Response High With Obe-Cel in B-Cell Acute Lymphoblastic Leukemia
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 11, 2024 -- For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, results in a high incidence of durable response, according to a study published online Nov. 27 in the New England Journal of Medicine.
Claire Roddie, M.D., from University College London, and colleagues conducted a phase 1b-2 multicenter study of obe-cel in 153 adults with relapsed or refractory B-cell ALL. Patients in cohort 2A (94 patients) had morphologic disease, while those in cohort 2B had measurable residual disease.
Overall, 127 patients received at least one infusion of obe-cel and were evaluable. The researchers found that overall remission occurred in 77 percent of patients in cohort 2A, with complete remission in 55 percent and complete remission with incomplete hematologic recovery in 21 percent. The prespecified null hypotheses (overall remission [≤40 percent] and complete remission [≤20 percent]) were rejected. The median event-free survival was 11.9 months in the 127 patients who received at least one obe-cel infusion, while the estimated six- and 12-month event-free survival was 65.4 and 49.5 percent, respectively. The median overall survival was 15.6 months, with 80.3 and 61.1 percent estimated six- and 12-month overall survival, respectively. In 2.4 percent of the patients, grade 3 or higher cytokine release syndrome developed, while grade 3 or higher immune effector cell-associated neurotoxicity syndrome developed in 7.1 percent.
"Obe-cel was associated with durable responses, particularly in patients with a low-to-intermediate bone marrow burden, including patients who did not receive consolidative allogeneic stem-cell transplantation," the authors write.
The study was funded by Autolus Therapeutics.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing...
Neurocognitive Battery Feasible in 3-Year-Olds During Leukemia Treatment
WEDNESDAY, Dec. 18, 2024 -- A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published online...
ASH: Blinatumomab + Chemo Aids Survival in B-Cell Acute Lymphoblastic Leukemia
THURSDAY, Dec. 12, 2024 -- For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for relapse, adding blinatumomab...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.